Yoga and compassion meditation program improve quality of life and self-compassion in family caregivers of Alzheimer's disease patients: A randomized controlled trial

2015 ◽  
Vol 17 (1) ◽  
pp. 85-91 ◽  
Author(s):  
Marcelo AD Danucalov ◽  
Elisa H Kozasa ◽  
Rui F Afonso ◽  
José CF Galduroz ◽  
José R Leite
Keyword(s):  
Quality Of Life ◽  
Alzheimer’S Disease ◽  
Randomized Controlled Trial ◽  
Family Caregivers ◽  
Controlled Trial ◽  
Improve Quality ◽  
Randomized Controlled ◽  
Self Compassion ◽  
Compassion Meditation

Does a regular nurse‐led distress screening and discussion improve quality of life of breast cancer patients treated with curative intent? A randomized controlled trial

2020 ◽  
Vol 29 (4) ◽  
pp. 719-728 ◽  
Author(s):  
Floortje K. Ploos van Amstel ◽  
Marlies E. W. J. Peters ◽  
Rogier Donders ◽  
Margrethe S. Schlooz‐Vries ◽  
Lenny J. M. Polman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Improve Quality ◽  
Breast Cancer Patients ◽  
Distress Screening ◽  
Curative Intent ◽  
Randomized Controlled

Taking charge after stroke: promoting self-directed rehabilitation to improve quality of life – a randomized controlled trial

2011 ◽  
Vol 26 (6) ◽  
pp. 493-501 ◽  
Author(s):  
Matire Harwood ◽  
Mark Weatherall ◽  
Api Talemaitoga ◽  
P Alan Barber ◽  
John Gommans ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Improve Quality ◽  
Randomized Controlled ◽  
Taking Charge

scholarly journals Examining the benefits and harms of Alzheimer’s disease screening for family members of older adults: study protocol for a randomized controlled trial

2019 ◽  
Author(s):  
Nicole Fowler ◽  
Katherine J. Head ◽  
Anthony J. Perkins ◽  
Sujuan Gao ◽  
Christopher M. Callahan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Alzheimer’S Disease ◽  
Older Adults ◽  
Alzheimer's Disease ◽  
Randomized Controlled Trial ◽  
Early Detection ◽  
Controlled Trial ◽  
Diagnostic Evaluation ◽  
Randomized Controlled

Abstract Background Multiple national expert panels have identified early detection of Alzheimer’s disease and related dementias (ADRD) as a national priority. However, the United States Preventive Services Task Force (USPSTF) does not currently support screening for ADRD in primary care given that the risks and benefits are unknown. The USPSTF stresses the need for research examining the impact of ADRD screening on family caregiver outcomes. Methods The Caregiver Outcomes of Alzheimer’s Disease Screening (COADS) is a randomized controlled trial that will examine the potential benefits or harms of ADRD screening on family caregivers. It will also compare the effectiveness of two strategies for diagnostic evaluation and management after ADRD screening. COADS will enroll 1,800 dyads, who will be randomized into three groups (n=600/group): Screening Only group will receive ADRD screening at baseline with disclosure of the screening results and a list of local resources for diagnostic follow-up; Screening Plus, ADRD screening at baseline coupled with disclosure of the screening results, with positive screen participants referred to a dementia collaborative care program for diagnostic evaluation and potential care; and Control, no screening. The COADS trial will measure the family member quality of life (primary outcome) and family member mood, anxiety, preparedness, and self-efficacy (secondary outcomes) at baseline, 6, 12, 18 and 24 months. Additionally, the trial will examine the congruence of depressive and anxiety symptoms between older adults and family members at 6, 12, 18 and 24 months and compare the effectiveness of two strategies for diagnostic evaluation and management after ADRD screening between the two groups randomized to screening (Screening Only versus Screening Plus). Discussion We hypothesize that caregivers in the screening arms will express higher levels of health-related quality of life, lower depressive and anxiety symptoms, and better preparation for caregiving with higher self-efficacy at 24 months. Results from this study will directly inform the National Plan to Address Alzheimer’s Disease, the USPSTF and other organizations regarding ADRD screening and early detection policies.

Sign in / Sign up

Export Citation Format

Share Document